Ascentage Pharma (6855 HK): Trials Progress, Olverembatinib, Lisaftoclax Gain Momentum in 1H26
Ascentage Pharma revenue up 29% to RMB 302.2M in 1Q26. R&D cost tread on a higher trajectory. Well positioned to accelerate market penetration and...
105 Views
Ascentage Pharma (6855 HK): Synthetic Expert Call Transcript (21 Jul 2026)
The $200M ATM ADS program filed on July 20, 2026, is a strategic necessity to buffer a massive $167.3M operating cash burn, driven by nine...
95 Views
Ascentage Pharma (6855 HK): ADS Offering Justified, 2027 Likely To Be An Inflection Point
​Ascentage Pharma plans to raise up to US$200M through ADS offering. Olverembatinib, Lisaftoclax gradually gaining momentum. 2027 likely to be an...
127 Views
Ascentage Pharma (6855 HK): 2026 Will Be Crucial, Olverembatinib and Lisaftoclax To Gain Momentum
​Ascentage Pharma reported revenue decline in 2025 due to high base effect. Olverembatinib and Lisaftoclax shine. Focus is on global Phase III...
123 Views
APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream
Akeso’s ivonescimab and Daiichi Sankyo’s Enhertu got additional indications approvals in China. CSPC Pharma’s mpox mRNA vaccine candidate got FDA...
107 Views